Molecular epidemiology of multiple drug resistant type 6B Streptococcus pneumoniae in the Northern Territory and Queensland, Australia by Carlisle, J. B. et al.
Copyright by the Cambridge University Press 
J. B. CARLISLE, M. GRATTEN and A. J. LEACH (2001). Molecular 
epidemiology of multiple drug resistant type 6B Streptococcus 
pneumoniae in the Northern Territory and Queensland, Australia. 
Epidemiology and Infection, 126, pp 25-29. 
doi:10.1017/S0950268801005106. 
 
Epidemiol. Infect. (2001), 126, 25–29. Printed in the United Kingdom # 2001 Cambridge University Press
Molecular epidemiology of multiple drug resistant type 6B
Streptococcus pneumoniae in the Northern Territory and
Queensland, Australia
J. B. CARLISLE"*, M. GRATTEN" and A. J. LEACH#
"Bacteriology, Queensland Health Scientific Serices, Brisbane, Queensland, Australia
#Menzies School of Health Research, Casuarina, Northern Territory, Australia
(Accepted 6 September 2000)
SUMMARY
The emergence of type 6B Streptococcus pneumoniae resistant to five antibiotics (penicillin,
chloramphenicol, trimethoprim–sulphamethoxazole, erythromycin and tetracycline) in both the
Northern Territory and Queensland prompted an investigation of the genetic relatedness and
patterns of migration of the isolates. Pulsed field gel electrophoresis of genomic DNA of 74
multiple drug-resistant (MDR) isolates cultured in both regions between August 1988 and June
1997 showed that 100% of MDR isolates from the Northern Territory and 96% of MDR
strains from Queensland were genetically indistinguishable or closely related to the index strain.
None of a further 65 type 6B isolates that were resistant to one or two, or susceptible to all of
the above antibiotics, were clonally related to the MDR pneumococci. The geographical
distribution of the MDR type 6B clone increased over time. The index strain, first isolated in
Darwin in August 1988, was identified in Brisbane, 2900 km distant, less than 4 years later and
subsequently in other Queensland centres. Surveillance programmes are important to monitor
the emergence and spread of potentially invasive MDR pneumococcal clones in countries that
are well serviced by air and road transport.
INTRODUCTION
Streptococcus pneumoniae resistant to three or more
classes of antibiotics were first recognized in South
Africa in 1977 [1] and subsequently elsewhere [2].
Several serotypes, including types 6B and 23F, readily
develop multiple resistance [3]. The ability of such
types to migrate to geographically distant regions is
associated with their predilection for colonizing the
upper respiratory tract (URT) of young children and
family contacts [4–6]. The clonality of multiply drug
resistant pneumococci has been established by ana-
lysing macrorestriction fragment digests of genomic
DNA by procedures such as pulsed-field gel electro-
phoresis (PFGE) [4, 7, 8]. In Australia, type 6B
pneumococci resistant to penicillin, chloramphenicol,
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trimethoprim–sulphamethoxazole (TMP–SMX), ery-
thromycin and tetracycline were first identified in
Darwin, Northern Territory in August. Further
strains with the same type and antibiogram were
recovered from the nasopharynx of Northern Ter-
ritory Aboriginal infants by Leach and co-workers in
1992–4 [9] and from hospitalized subjects in Darwin
from 1991. In the course of a Queensland-based
pneumococcal surveillance programme [10], pheno-
typically similar pneumococci were first encountered
in Brisbane (South East Queensland) and Cairns
(North Queensland) in 1992 and 1995 respectively and
subsequently, in other centres in Queensland. It was
decided to investigate the clonality of these multiple
drug resistant type 6B (MDR6B) pneumococci and
their migration patterns by examining isolates, using
PFGE, from Queensland and the three sources in the
Northern Territory described above.
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METHODS
Bacterial strains
Seventy-four isolates of MDR6B pneumococci were
studied. Of these, 28 strains represented 64% of the
MDR6B isolates from the Darwin region of the
Northern Territory and 46 strains, represented 85%
of the MDR isolates from Queensland. These strains
were cultured from August 1988 to April 1994
(Darwin region, Northern Territory) and from May
1992 to June 1997 (Queensland). Fifteen isolates were
recovered from normally sterile sites (blood and}or
CSFfl 14, joint aspiratefl 1) or other sites (sputum
fl 29, upper respiratory tract (URT) secretionsfl 18,
earfl 6, eyefl 3, lung post mortemfl 1, bronchusfl
1). The source of one isolate was unknown. Two
isolates were recovered from the same patient ad-
mitted on separate occasions to different hospitals.
Further type 6B isolates including 25 strains
susceptible to penicillin, chloramphenicol, TMP–
SMX, erythromycin and tetracycline and 40 strains
resistant to 1 (TMP–SMX, nfl 25) or 2 (penicillin and
TMP–SMX, nfl 15) were also examined in order to
assess the genetic heterogeneity within and between
antibiogram categories. These strains were cultured
from normally sterile sites (blood and}or CSFfl 52)
and other sources (sputumfl 2, URT secretionsfl 7,
earfl 2, eyefl 2) from patients in South East Queens-
land (39 isolates), North Queensland (18) and the
Darwin region (8) from June 1991 to September 1997.
Identification
Pneumococci were identified presumptively by Gram
stain, colonial morphology on blood agar, and
optochin susceptibility. They were typed by the
Quellung reaction with antisera raised at Statens
Seruminstitut, Copenhagen, Denmark as described
elsewhere [11].
Antibiotic susceptibility testing
The Etest (AB Biodisk, Solna, Sweden) was used as
described elsewhere [12] and interpreted according to
the National Committee for Clinical Laboratory
Standards performance standards [13].
Pulsed-field gel electrophoresis
PFGE is the preferred strain typing procedure for S.
pneumoniae [14]. The method used follows those as
described by Lefevre et al. [15] and Matushek et al.
[16] with the following modifications.
Penumococcal isolates were grown at 36–5 °C in
10 ml of brain heart infusion broth (Becton Dickinson
and Co., Cockeysville, MD) supplemented with 10%
non-inactivated donor horse serum (CSL Biosciences,
Parkville, Victoria, Australia) to an optical density of
0–4–0–8 at 590 nm. The agarose gel was electro-
phoresed using the Gene Navigator System (Pharm-
acia Biotech AB) for 24 h at 170 V with pulse times
stepped at 5 s (9 h), 20 s (9 h) and 40 s (6 h). The
interpretation of banding profiles and categories of
genetic relatedness followed the recommendations of
Tenover et al. [17].
RESULTS
Antimicrobial susceptibility
The minimal inhibitory concentration (MIC) ranges
(lg}ml) of 5 antibiotics for 74 MDR6B isolates were
penicillin, 0–5–2–0; chloramphenicol, 16–64; TMP–
SMX, 4–32}76–608; erythromycin, 256; tetracycline,
16–128. The tetracycline MIC for one isolate was not
done. Of a further 65 type 6B pneumococci, 25 strains
were susceptible to all antibiotics, 25 strains were
resistant to TMP-SMX only (MIC range 1–19 to
32–608 lg}ml), and 15 strains were resistant to
both penicillin and TMP-SMX (MIC ranges 0–125–
1–0 lg}ml and 1–19}4–76 lg}ml, respectively).
Pulsed-field gel electrophoresis
For the genomic DNA fragment analysis of MDR6B
isolates the initial MDR6B strain recognized in
Darwin in August 1988 was selected as the index
strain with which other MDR6B isolates were com-
pared. Comparison of the fragment profiles of 74
strains demonstrated a high level of homogeneity
(Fig. 1). Overall, 97% were genetically indistinguish-
able (27%) or closely related (70%) to the index
isolate. The remaining 3% of isolates were possibly
related to the index isolate. Regionally, 59% of
Darwin pneumococci were indistinguishable from the
index strain. While only 9% of Queensland isolates
were indistinguishable to the index strain, 87% were
closely related to it genetically. None of 65 type 6B
pneumococci with broad-spectrum antibiotic suscep-
tibility (25 strains) or resistance to 1 drug (25 strains)
or 2 drugs (15 strains), was genetically related to the
index strain.
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Fig. 1. Genetically related pulsed field gel electrophoresis
profiles of DNA Sma1 digests of type 6B S. pneumoniae
strains from the Darwin region, Northern Territory (lanes 2,
3, 4, 7) and Queensland (lanes 5, 6, 8). Lane 1 (S.
pneumoniae, ATCC 49619) is the reference strain. Lane 4 is
the index strain, NT 1. Lane 9 is the k-DNA ladder with the
sizes (in kilobases) indicated to the right.
Migration patterns of clonal MDR6B pneumococci
The first MDR6B pneumococcus was isolated in
Darwin in August 1988. A strain with a genotype
similar to that of the index case was first identified in
Queensland in a 72-year-old patient hospitalized with
bacterial meningitis in Brisbane in May 1992. Other
initial MDR6B isolates in Queensland, by major
centre, followed: Cairns (North Queensland) Febru-
ary 1995, Mackay (Central Queensland) October
1995, Gold Coast (south of Brisbane) March 1996,
and Townsville (North Queensland) October 1996.
The Townsville isolate was genetically indistinguish-
able from a strain cultured from the same patient
while hospitalized in Brisbane in October 1995. The
possible migration routes are outlined in Figure 2.
Regular air services exist between Darwin and
Brisbane then north from Brisbane to other major
Queensland centres. There is also an excellent road
network interstate.
DISCUSSION
This study shows that a clone of multiple drug-
resistant type 6B pneumococci, first isolated in Darwin
in 1988, subsequently emerged in major Queensland
centres during 1992–7. The inter-country migration of
antibiotic resistant pneumococcal clones, such as
types 6B and 23F, to geographically distant areas is
well documented [4, 5]. The spread of a type 6B clone
from the Darwin region to Queensland is thus not
surprising since the greatest distance between Darwin
and any major Queensland centre does not exceed
4000 km. The Northern Territory and Queensland are
geographically contiguous and well served by air and
road services. While precise routes of clonal migration
are unclear, the identification in Brisbane of a strain
which was genetically indistinguishable from that of
the index case, before other isolations elsewhere in
Queensland, suggests direct spread from Darwin to
Brisbane.
The dispersal of pneumococci such as group 6 types
is favoured since upper airway carriage by these
organisms is common, particularly in young children
in both industrialized and developing countries.
Carriage is of high density and of long duration
[18, 19]. The epidemiology of meningitis due to
multiple drug-resistant 6B pneumococci has also been
investigated in an infant day care centre. This study
determined the susceptibility for upper respiratory
tract carriage of the index strain by close contacts
including other children, staff and family contacts of
the colonized children [6]. It is clear that once
established in Queensland a 6B clone with the
epidemiological characteristics of a common and
tenacious carriage organism is likely to spread readily
between cities in the highly populated eastern sea-
board of Queensland.
Evidence of random genetic events which have
altered the PFGE profiles of multiple drug-resistant
6B strains isolated during the course of this study have
been noted. Genetic diversity increased as the study
progressed. While 59% of 27 Northern Territory
strains isolated during 1988–94 were indistinguishable
to the index strain, minimal fragment differences were
observed in other Northern Territory strains and in
87% of 46 genetically related Queensland isolates
cultured during 1992–7. Such changes are common,
are known to occur naturally over time and result
from point mutations and insertions and deletions of
DNA [17]. Nonetheless, the general stability of
multiple drug resistant type 6B clones over time and in
widely separated geographic locations has been
reported [20].
Type 6B pneumococci with different antibiograms
from those of the test strains were included in the
current study for comparative purposes. All strains
were shown to be genetically diverse and unrelated to
the multiple drug-resistant type 6B strains.
Multiple drug resistant pneumococci such as type
6B create a clinical dilemma because of their ability,
not only to colonize the upper respiratory tract, but
also to invade normally sterile sites. In our study 20%
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Fig. 2. Dates and referral centres of the first isolations of clonally related multiple drug-resistant type 6B Streptococcus
pneumoniae, and inter-centre distances (km), in the Northern Territory and Queensland, Australia. The numbers 1–6 adjacent
to each referral centre represents the chronological order of migration of the MDR6B clones.
of 74 isolates were cultured from blood (12 strains),
CSF (2 strains) and joints (1 strains). The ability of
multiple drug resistant pneumococcal clones to spread
widely highlights the importance of surveillance
programmes that monitor the type distribution and
drug resistance of both carriage and invasive types.
The use of conjugate pneumococcal vaccines in young
children may reduce the emergence and spread of
multiple drug resistant clones [21].
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